BioPharm International Editors

Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics is expected to strengthen its sickle cell disease portfolio.

Sartorius’ £415 million (US$429 million) acquisition of Albumedix is intended to bolster its portfolio with recombinant albumin-based solutions.

Catalent will acquire Metrics Contract Services for $475 million to expand high-potent capabilities and oral development and manufacturing capacity.

FDA has approved Coherus’ Cimerli (ranibizumab-eqrn) as an interchangeable biosimilar for all five indications of Lucentis.

Sanofi and Innovent have entered into a strategic collaboration to accelerate development of oncology medicines and expand their presence in China.

Amgen’s acquisition of Chemocentryx includes the autoimmune disease drug Tavneos (avacopan).

The OMNI Electric Utility Raceway power and data management system is designed to reduce risk and accelerate cleanroom delivery.

La Jolla’s acquisition of Carterra’s LSA Platform is designed to advance their immunological and infectious disease research.

Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.

Ipsen and Marengo Therapeutics will collaborate to advance two precision immuno-oncology candidates.

CRYOPDP is expanding its footprint to Spain with its acquisition of Polar Expres.

Bio-Rad has expanded its range of recombinant monoclonal anti-idiotypic antibodies.

The new facility in Albany, Ore., will support biopharmaceutical development and lyophilization services.

DuPont’s new manufacturing site will expand its biopharmaceutical tubing manufacturing capabilities.

The United States has agreed to purchase 66 million doses of Moderna’s bivalent COVID-19 booster candidate for $1.74 billion.

The European Commission has granted marketing authorization to Upstaza (eladocagene exuparvovec) for treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.

Shimadzu’s new ultra-high performance liquid chromatography system is designed to solve common problems in biopharma analysis.

Roche’s new test is the first available immunoassay that allows for simultaneous, independent determination of the hepatitis C virus antigen and antibody status.

WuXi STA is opening a new large-scale oligonucleotide and peptide manufacturing facility.

Discovery Life Sciences’ acquisition of AllCells is intended to bolster its cell and gene therapy products and services.

AstraZeneca's acquisition of TeneoTwo will give the company access to its clinical-stage T-cell engager, TNB-486, strengthening their hematological cancer pipeline.

WHO has determined that monkeypox constitutes a public health emergency of international concern.

The agency’s human medicines committee recommended drugs to treat breast cancer, lupus nephritis, type 2 diabetes and more.

A joint statement calling for international collaboration on the creation and use of real-world evidence has been published by the International Coalition of Medicines Regulatory Authorities.

Hospira has issued a voluntary nationwide recall for one lot of Propofol Injectable Emulsion, USP (containing benzyl alcohol), due to the potential presence of visible particulate.

TFF Pharmaceuticals is expanding its R&D operations with a new facility in Austin, Texas.

The PerkinElmer Flow Cytometry Instrument Concierge Services will provide biopharmaceutical labs with expert, on-site flow cytometry specialists.

Cytiva has acquired a new chromatography resins manufacturing site in the United States as part of its $1.5 billion capacity expansion investment.

Health Canada has authorized Moderna’s COVID-19 vaccine for use in young children aged six months to five years.

Royalty Pharma is paying $1.6 billion for the royalty rights to Trelegy Ellipta, a treatment for COPD and asthma.